https://scholars.lib.ntu.edu.tw/handle/123456789/461884
標題: | Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer | 作者: | YU-TING CHANG MING-CHU CHANG SHU-CHEN WEI YU-WEN TIEN CHIUN HSU PO-CHIN LIANG PO-NIEN TSAO I-SHIOW JAN Wong J.-M. |
公開日期: | 2008 | 卷: | 37 | 期: | 2 | 起(迄)頁: | 145-150 | 來源出版物: | Pancreas | 摘要: | OBJECTIVES: Tumor angiogenesis is the consequence of an imbalance between positive and negative angiogenic regulatory factors. We sought to determine the role of pretreated serum angiogenic factors, including vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and soluble vascular endothelial growth factor receptor 1 (sVEGFR-1), in predicting clinical outcome in patients with pancreatic cancer. METHODS: We assessed pretreated serum VEGF, PlGF, and sVEGFR-1 levels in 92 patients with pancreatic adenocarcinoma and 60 healthy control subjects using an enzyme-linked immunosorbent assay. The correlation between these angiogenesis-related factors and clinicopathologic factors, including staging and overall survival, was analyzed. RESULTS: Serum levels of VEGF, PlGF, and sVEGFR-1 were significantly higher in patients with pancreatic cancer compared with those in controls (583.8 ± 559.5 vs 187.63 ± 393.32, 17.65 ± 7.34 vs 10.93 ± 1.21, and 50.94 ± 51.17 vs 15.55 ± 1.98 pg/mL, respectively; P < 0.0001). A reverse correlation was observed between sVEGFR-1 level and the advance of tumor stage. Cox regression analysis showed that the VEGF/sVEGFR-1 ratio was an independent predictor for pancreatic cancer survival. Higher VEGF/sVEGFR-1 ratio was significantly correlated with poor outcome in patents with pancreatic cancer. CONCLUSIONS: Vascular endothelial growth factor/sVEGF-1 ratio is an independent prognostic factor for survival in pancreatic cancer. Its significance should be assessed when considering antiangiogenic therapy in treating pancreatic cancer patients. Copyright ? 2008 by Lippincott Williams & Wilkins. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-55949086925&doi=10.1097%2fMPA.0b013e318164548a&partnerID=40&md5=019e18f9162a666b04a4713f7ae2d788 https://scholars.lib.ntu.edu.tw/handle/123456789/461884 |
ISSN: | 0885-3177 | DOI: | 10.1097/MPA.0b013e318164548a | SDG/關鍵字: | placental growth factor; vasculotropin; vasculotropin receptor 1; placenta protein; product placenta growth factor; tumor marker; vasculotropin A; vasculotropin receptor 1; VEGFA protein, human; adult; aged; angiogenesis; article; cancer survival; clinical assessment; controlled study; disease marker; disease severity; enzyme linked immunosorbent assay; female; human; major clinical study; male; outcome assessment; overall survival; pancreas adenocarcinoma; prediction; priority journal; prognosis; protein blood level; protein function; adenocarcinoma; blood; case control study; middle aged; mortality; neovascularization (pathology); pancreas tumor; solubility; survival rate; Taiwan; vascularization; Adenocarcinoma; Aged; Case-Control Studies; Female; Humans; Male; Middle Aged; Neovascularization, Pathologic; Pancreatic Neoplasms; Pregnancy Proteins; Prognosis; Solubility; Survival Rate; Taiwan; Tumor Markers, Biological; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。